CIMZIA is available under pharmacy and medical benefits in 2 flexible administration options
Click to enlarge
CIMZIA is administered by subcutaneous injection. There are 2 options for administration of CIMZIA.
The recommended initial dose of CIMZIA for adults with moderate to severe CD is 400 mg (given as 2 subcutaneous injections of 200 mg) initially and at weeks 2 and 4. In patients who obtain a clinical response, the recommended maintenance regimen is 400 mg every 4 weeks.
Indication CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
Important Safety Information Rare reports of blood dyscrasias have been reported with CIMZIA; patients should be advised to seek medical attention if they develop.
Concurrent administration of CIMZIA with certain biological DMARDs, including anakinra, abatacept and rituximab is not recommended due to an increase risk of serious infections.
In pre-marketing controlled trials of all patient populations combined the most common adverse reactions (≥8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).
NEXT: Low Injection Site Pain »